Data by Industry within Healthcare Sector
|
|
Marketcap |
Revenues (TTM) |
Net Income (TTM) |
Employees |
Industry |
(Millions) |
(Millions) |
(Millions) |
Number |
Biotechnology & Pharmaceuticals Industry |
$ 557,280 |
$ 90,441 |
$ 3,925 |
76,397 |
Healthcare Facilities Industry |
$ 251,126 |
$ 212,163 |
$ 7,544 |
1,070,159 |
Major Pharmaceutical Preparations Industry |
$ 3,864,652 |
$ 674,026 |
$ 59,558 |
1,108,224 |
Medical Equipment & Supplies Industry |
$ 1,349,386 |
$ 304,389 |
$ 9,382 |
755,166 |
Medical Laboratories Industry |
$ 270,853 |
- |
$ 2,131 |
382,633 |
Laboratory Analytical Instruments Industry |
$ 145,976 |
$ 36,820 |
$ -50 |
65,904 |
In Vitro & In Vivo Diagnostic Substances Industry |
$ 98,000 |
$ 10,799 |
$ -184 |
19,244 |
Healthcare Sector |
$ 6,537,273 |
- |
$ 82,307 |
3,477,727 |
Recent News from Healthcare Sector |
Clinical Study
XORTX Therapeutics Inc.: A Promising Future for Progressive Kidney Disease TreatmentXORTX Therapeutics Inc. (XORTX), a leading clinical pharmaceutical company, has achieved significant milestones in 2023 and is poised to make even greater strides in 2024. With a strong focus on developing innovative therapies to combat progressive kidney disease, XORTX is...
|
|
Announcement
In a recent update, ObsEva, a leading biopharmaceutical company focused on women's reproductive health, announced changes to its Board of Directors. These developments, along with a subsequent court ruling, have significant implications for the company's future operations.ObsEva revealed that effective immediately, three new members have joined its Board ...
|
|
Financing Agreement
Madrigal Pharmaceuticals Announces Upsized $600 Million Public Offering and Record Net Loss CONSHOHOCKEN, Pa., March 18, 2024 - Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a leading biopharmaceutical company specializing in novel therapeutics for nonalcoholic steatohepatitis (NASH), recently disclosed the pricing of its underwritten public offering...
|
|
Contract
In a strategic move to expand its edge metal and non-insulated architectural wall systems business, Carlisle Companies Incorporated announced today its definitive agreement to acquire MTL Holdings from GreyLion Partners, a prominent private equity firm. The acquisition of MTL, a leading provider of pre-fabricated edge metal for commercial roofing systems,...
|
|
Personnel Announcements
Delcath Systems Announces Martha S. Rook as New Chief Operating Officer NEW YORK, March 18, 2024 - Delcath Systems, Inc., a leading interventional oncology company specializing in the treatment of primary and metastatic cancers of the liver, has recently appointed Martha S. Rook as its new Chief Operating Officer (COO). This strategic move is expected...
|
|
Financing Agreement
Iselin-based biopharmaceutical company, Outlook Therapeutics, has successfully concluded its private placement, securing upfront gross proceeds of approximately $60 million. In addition, the company has the potential to further bolster its financial position with up to $99 million upon the exercise of warrants issued in the private placement. Th...
|
|
Exagen Inc
Exagen Inc (Nasdaq: XGN) has shown significant signs of weakness in its latest financial report for the fourth quarter of 2023. Despite a decrease in the loss per share compared to the previous year, the company still reported a loss of $-0.30 per share. This is only a slight improvement from the loss of $-0.83 per share in the same period a year prior.
|
|
Leap Therapeutics Inc
Leap Therapeutics Inc, a major pharmaceutical preparations company, recently reported its financial results for the October to December 31, 2023 reporting season. While shareholders had not anticipated any significant changes, they were disappointed to observe an operating deficit of $14.82 million during this period. This represents a decline compared to...
|
|
Cyclo Therapeutics Inc
Cyclo Therapeutics Inc, a Biotechnology and Pharmaceuticals company, has shown positive growth in the fourth quarter of 2023, despite industry-wide challenges. In its December 31, 2023 report, the company reported a significant revenue rise of 66.699% to $0.31 million. This increase in revenue has helped the company reduce its losses to $-0.18 per share, ...
|
|
Dividend
Homology Medicines Declares Distribution to Common Stockholders Homology Medicines, Inc. (Nasdaq: FIXX) has declared a distribution to its common stockholders of record as of March 21, 2024, granting them the right to receive one contingent value right (CVR) for each outstanding share of Homology common stock held. The payment date for this distributi...
|
|
|
|
|
|